Daewoong Pharmaceutical Collaborates with Seoul National University Bundang Hospital and 365mc to Expand VOILET Indications

Investigator-Initiated Trial Targeting Anterior Axillary Fat Underway

Expanding Indications Beyond Double Chin

Meeting the Growing Demand for "Micro-Beauty" Amid GLP-1 Drug Proliferation

Daewoong Pharmaceutical announced on July 16 that it has signed a memorandum of understanding (MOU) with Seoul National University Bundang Hospital and 365mc for the development of new indications for the fat-dissolving injectable, "VOILET."

(from left) Junsu Yoon, Head of Nabota Business Division at Daewoong Pharmaceutical, Namcheol Kim, CEO of 365mc Co., Ltd., and Changhoon Hur, Professor of Dermatology at Seoul National University Bundang Hospital, are signing. Daewoong Pharmaceutical

VOILET, an injectable drug containing deoxycholic acid (DCA), is currently approved for the treatment of submental fat (double chin). Through this agreement, Daewoong Pharmaceutical plans to expand VOILET’s indications to various localized fat areas, beginning with the anterior axillary fat and extending to the abdomen, arms, and thighs.

This research initiative was launched in response to the increasing demand for managing localized fat and decreased skin elasticity following weight loss, a trend driven by the recent proliferation of GLP-1-based anti-obesity drugs.

Professor Changhun Heo's research team at the Department of Dermatology, Seoul National University Bundang Hospital, will conduct an investigator-initiated trial (IIT) to evaluate the efficacy of VOILET in reducing anterior axillary fat. The trial has received both Investigational New Drug (IND) approval from the Ministry of Food and Drug Safety and Institutional Review Board (IRB) approval, and is about to commence.

Based on its extensive clinical data in the fields of liposuction and body contouring, 365mc participated in the development of evaluation indicators for anterior axillary fat reduction during the IND approval process. Daewoong Pharmaceutical will support collaborative research by leveraging its market experience and research and development capabilities with VOILET.

VOILET is a deoxycholic acid injection that directly destroys fat cells. Daewoong Pharmaceutical stated that more than 200,000 vials have been sold so far, and the product is supplied to over 2,000 clinics and hospitals nationwide.

Junsu Yoon, Head of the Nabota Business Division at Daewoong Pharmaceutical, said, “By launching this joint research initiative, we aim to expand VOILET's indications and lead the evidence-based body contouring market.”

This content was produced with the assistance of AI translation services.